undamentalytics Newsletter
Sign in

Innoviva, Inc. cash flow statement

In fiscal 2025, Innoviva, Inc.'s operations generated $197m of cash; it spent $1.1m on capital projects, leaving free cash flow of $196m. It returned $4.5m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−58−75−88−128−130−1311061142224257313364202141189197191
Depreciation and amortisation668331214141414141414—————
Stock-based pay20192524262778103222766912
Capital spending114331000000000012
Free cash flow−59−76−92−130−132−1311061142224257313364202141188196189
Free cash flow after stock pay−79−95−117−154−158−159352132220255311362194135182186177
Dividends paid———005787100000—————
Share buybacks————0026789800039497615556
Shares issued122312623615355800110100133

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: INVA vs IRWDINVA vs XERSALVO vs INVA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Innoviva, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innoviva, Inc.